- Home
- MPB vs PLRX Comparison
MPB vs PLRX Comparison
Compare MPB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | PLRX |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 79.9M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MPB | PLRX |
|---|---|---|
| Price | $31.29 | $1.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $37.00 | $2.50 |
| AVG Volume (30 Days) | 103.8K | ★ 601.2K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 2.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.55 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | $18.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $1.09 |
| 52 Week High | $35.22 | $1.95 |
Technical Indicators
Market Signals| Indicator | MPB | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 57.45 |
| Support Level | $30.69 | $1.12 |
| Resistance Level | $31.75 | $1.36 |
| Average True Range (ATR) | 0.92 | 0.06 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 21.88 | 58.14 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.